Coronavirus / COVID

Latest News

FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Post-Exposure Prevention
FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Post-Exposure Prevention

September 2nd 2025

Supported by Phase 3 SCORPIO-PEP trial data, ensitrelvir could become the first oral therapy to prevent COVID-19 following exposure, with an FDA decision due June 16, 2026.

FDA Approves Moderna’s Updated COVID-19 Vaccines Targeting LP.8.1 Variant for Fall 2025
FDA Approves Moderna’s Updated COVID-19 Vaccines Targeting LP.8.1 Variant for Fall 2025

August 29th 2025

FDA Approves Updated COVID-19 Vaccines for Fall 2025, Restricts Eligibility to High-Risk Groups
FDA Approves Updated COVID-19 Vaccines for Fall 2025, Restricts Eligibility to High-Risk Groups

August 29th 2025

CDC Confirms Biannual COVID-19 Peaks as ACIP Shifts to Targeted Vaccination Guidance
CDC Confirms Biannual COVID-19 Peaks as ACIP Shifts to Targeted Vaccination Guidance

August 22nd 2025

Wearable Devices Capture Biometric Patterns in Long COVID
Wearable Devices Capture Biometric Patterns in Long COVID

August 22nd 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.